The global hyperparathyroidism treatment market size is expected to be worth USD 835.5 Million in 2025. It can reach a valuation of USD 1,350.4 Million by 2032. The market is anticipated to peak at a CAGR of 7.1% during the forecast period (2025-2032).  

The surge in hyperparathyroidism (HPT) among postmenopausal women and the demand for therapies for the treatment of secondary HPT can drive the market growth. Additionally, advances in diagnostic tools and success in minimally invasive surgeries can augur favorably for the market.

However, the high costs of treatment and the side effects of calcimimetics can be a hurdle to the market growth.

Key Market Insights

The hyperparathyroidism treatment market is predicted to scale owing to the rise of endocrine diseases, the use of targeted therapies, and the development of orphan drugs.

• By product, the vitamin D analogue segment is expected to score 23.0% market share in 2025. This can be attributed to the use of vitamin D analogues for the treatment of secondary hyperparathyroidism (SHPT). But the segment’s growth can be limited owing to the drugs’ effect on calcium and phosphorus levels.
• By route of administration, the intravenous segment is anticipated to attain 21.0% market share in 2025. The segment growth is driven by the administration of calcimimetics in hemodialysis sessions and their use in the management of SHPT.
• By region, the Asia Pacific is projected to capture a significant market share in 2025, owing to significant investments in healthcare infrastructure and the rise of medical tourism. The high prevalence of chronic kidney disease (CKD) also plays a vital role in driving the market growth in the region.

The full report is now available for purchase: https://www.coherentmi.com/industry-reports/hyperparathyroidism-treatment-market

Hyperparathyroidism Treatment Market Report Coverage

Market Dynamics

The hyperparathyroidism treatment market is expected to be driven by the rise of rare endocrine disorders and the complications arising in the form of SHPT. The combination of calcimimetics and vitamin D analogues for the treatment of HPT in pediatric patients led to the launch of such products. This is witnessed by the approval of ORKEDIA tablets by Kyowa Kirin Group in Japan on August 30, 2023, and their distribution among patients with SHPT.

The use of long-acting PTH analogs and nanoparticle delivery systems for being precise with treatments can drive the market demand significantly. Assessment of novel drugs in clinical studies and development of advanced imaging methods can provide early prevention strategies in the market.

Market Opportunities: Popularity of miRNA Gene Therapies to Boost Market Growth

Targeted therapies at miRNA genes can change the expression of parathyroid glands and raise the potential of their development. The successful changes witnessed in gene expression in mice models can be used in the regulation of cell growth, metabolism, and differentiation. The need for the study on the pathogenesis of HPT and technical developments in miRNA gene therapy can open new opportunities for manufacturers in the hyperparathyroidism treatment market.

Market Challenge: Limited Drug Development Pipeline for HPT

The limited drug development for HPT, owing to the rise of a few drug candidates for approval, can continue to be a hurdle for the market. The shift towards SHPT and the lack of development of treatments for primary hyperparathyroidism can limit the market growth. This can be seen by the lack of any news of HPT treatments from 2024.

Analyst’s View

• The rise of rare endocrine disorders and targeted therapies for their treatment can drive the demand in the hyperparathyroidism treatment market.
• The intravenous segment is expected to carve a huge segment share in 2025, owing to its use in the administration of drugs in SHPT patients.
• Companies are focusing their efforts on partnerships, licensing, and expansion of reach. 

Recent Developments

OPKO Health, Inc. released the results of the effects of RAYALDEE, an extended-release calcifediol (ERC), on November 02, 2023. The data displayed the effective treatment of SHPT and the slowdown of the progression of CKD.

Competitor Insights

• Novartis AG
• Sanofi S.A.
• Roche Holding AG
• AbbVie Inc.
• OPKO Health, Inc.
• Radius Health Inc.
• Kyowa Kirin Co., Ltd.
• Pathalys Pharma
• Takeda Pharmaceutical Company Limited
• Shire Pharmaceuticals
• Amgen Inc.

Market Segmentation

• By Product
• Parathyroid Hormone
• Vitamin D Analogue
• Calcium Supplements
• By Route of Administration
• Oral
• Intravenous
• Subcutaneous

Regional Insights

• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Italy
  • Germany
  • U.K.
  • Spain
  • Russia
  • France
  • Rest of Europe
• Asia Pacific
  • South Korea
  • India
  • China
  • Japan
  • Australia
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa